INTERIM REPORT FOR Q1 2024/25
In the first quarter of the 2024/25 financial year, Ambu delivered
19.5% organic revenue growth and a 16.1% EBIT margin before
special items, driven by continued solid momentum in Endoscopy
Solutions, which grew by 20.6%, and strong performance in
Anaesthesia & Patient Monitoring, which grew by 17.8%, mainly
related to price increases and solid volume growth.
HIGHLIGHTS FOR Q1 2024/25
Last year’s comparative figures are presented in brackets.
Financial highlights
On January 9, 2025, Ambu adjusted its full-year financial guidance
by upgrading the expectations for organic revenue growth to 11-
14% (previously 10-13%) and for EBIT margin before special items to
13-15% (previously 12-14%). The upgrade was mainly related to
strong performance in Anaesthesia & Patient Monitoring, supported
by continued solid growth in Endoscopy Solutions.
“I am pleased with the strong start we have had to the financial year,
delivering growth and profitability above expectations and achieving
notable milestones. We continued our strong momentum in Endoscopy
Solutions, with robust pulmonology growth, and delivered significant
performance improvement in Anaesthesia & Patient Monitoring.
Revenue increased organically by 19.5% (14.2%) to DKK 1,510m (DKK 1,254m), with
reported growth of 20.4% (10.9%).
Endoscopy Solutions revenue increased organically by 20.6% (25.1%). Pulmonology
posted 17.7% (18.1%) organic growth, and urology, ENT and GI posted 23.9% (34.2%)
organic growth, combined.
Anaesthesia & Patient Monitoring increased organically by 17.8% (1.2%), positively
impacted by price increases and solid volume growth.
EBIT before special items (b.s.i.) was DKK 243m (DKK 126m), with an EBIT margin b.s.i.
of 16.1% (10.0%). The increase was primarily driven by organic revenue growth.
Free cash flow before acquisitions totalled DKK 69m (DKK 135m). This was positively
impacted by increased profitability and trade payables, although offset by increased
In 2025, we will launch our new video laryngoscopy solution, Ambu®
SureSightTM Connect, expanding our pulmonology portfolio with a
unique offering. With bioplastics now in all our endoscope handles, I’m
excited for another year of supporting customers with innovative
solutions that improve patient care, together with my Ambu colleagues
worldwide.“
inventory levels, due to preparations pertaining to new product launches, higher trade
receivables, as well as higher investments.
At Ambu’s annual general meeting 2024, it was decided to pay out dividends worth
DKK 102m (DKK 0.38 per share).
The adjusted 2024/25 financial guidance, stated on 9 January 2025, is maintained:
- Organic revenue growth: 11-14%
Britt Meelby Jensen
Chief Executive Officer
- Reported EBIT margin before special items: 13-15%
- Free cash flow: DKK +500m
Business highlights
Strengthened pulmonology offering with the registration of Ambu® SureSight™
Connect, Ambu’s new video laryngoscopy solution.
Commercial launch of Ambu’s ureteroscopy solution, Ambu® aScope™ 5 Uretero.
Q1 2024/25 conference call
Bioplastic materials implemented in the handle of all Ambu’s marketed endoscopes,
marking an important step in transforming the industry towards sustainable endoscopy.
A conference call is broadcast live today, 30 January 2025 at 11:00 (CET), via
ambu.com/webcastQ12025. To ask questions during the Q&A session,
please register prior to the call via ambu.com/conferencecallQ12025register.
Upon registration, you will receive an e-mail with information to access the call.
The presentation can be downloaded at Ambu.com/presentations.
2
Company announcement no. 11 2024/25 | 30 January 2025
